Company / Operating Margin
Inhibikase Therapeutics, Inc. Operating Margin History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-7712.0%
FY2024
5-year range
-14686.2% / -403.5%
FY2021-FY2024
Trend
+47.5%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin returned to growth in FY2024 after 2 years of decline, reaching -7712.0%.
Based on SEC 10-K filings.
-7712.0% in FY2024 with a 3-year CAGR of -7308.5%.
Declined from -476.2% to -7712.0% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- -7308.5pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, operating margin increased 47.5% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -7712.0% | +47.5% |
| FY2023 | -14686.2% | -2983.8% |
| FY2022 | -476.2% | -18.0% |
| FY2021 | -403.5% | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026